<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063149</url>
  </required_header>
  <id_info>
    <org_study_id>NL76165.100.20</org_study_id>
    <nct_id>NCT05063149</nct_id>
  </id_info>
  <brief_title>Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.</brief_title>
  <acronym>PROTEA</acronym>
  <official_title>Protecting Late-moderate Preterm Infants From Respiratory Tract Infections and Wheeze in Their First Year of Life by Using Bacterial Lysates.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Franciscus Gasthuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Franciscus Gasthuis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to reduce respiratory tract infections and wheezing in&#xD;
      moderate-late preterms in the first year of life by bacterial lysate administration. Next to&#xD;
      determine the correlation of biological markers with respiratory symptoms, immune protection&#xD;
      and treatment effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised placebo-controlled trial including 500 otherwise healthy moderate-late&#xD;
      preterm infants. Participants will receive bacterial lysate (Broncho-Vaxom, 3,5mg) or placebo&#xD;
      powder for ten days each month, from 6 weeks after birth until 12 moths of age. Clinical data&#xD;
      will be continuously collected by e-Health and 3 (possibly digital) study visits; with&#xD;
      optional biological sampling and lung function at baseline, 6 and 12 months. Main study&#xD;
      parameters are doctor diagnosed lower RTI and wheezing episodes in the first year of life.&#xD;
      Biological sampling will allow investigation of immune maturation, as well as microbiome&#xD;
      development in the respiratory tract and gut. Also, biomarkers for risk-group selection&#xD;
      and/or treatment success will be examined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Half of the participants (250) will receive treatment (Broncho-Vaxom) and the other half will receive placebo. Randomization will be stratified for gestational age (moderate (30+0-32+6) vs. late (33+0-35+6) prematurity).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study subjects, all study investigators including the principal investigator and treating physicians will be blinded for the allocation during the complete study period. The trial pharmacy has a deblinding key, which only will be requested in case of safety issues. After every participant has completed the study time and visits necessary for the primary endpoint, and after the database has been completed and locked with respect for the primary endpoint, the deblinding key will be released.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of physician diagnosed lower RTI and wheezing episodes in the first year of life</measure>
    <time_frame>In the first year of life.</time_frame>
    <description>Recorded by frequent questionnaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first lower RTI or wheezing episode</measure>
    <time_frame>In the first and second year of life.</time_frame>
    <description>Recorded by short weekly questionnaires (which will be filled in during the first year of life) and more extensive questionnaires every six months in the first and second year of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of RTI</measure>
    <time_frame>In the first and second year of life.</time_frame>
    <description>Recorded by short weekly questionnaires (which will be filled in during the first year of life) and more extensive questionnaires every six months in the first and second year of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of wheezing episodes</measure>
    <time_frame>In the first and second year of life.</time_frame>
    <description>Recorded by short weekly questionnaires (which will be filled in during the first year of life) and more extensive questionnaires every six months in the first and second year of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of viruses</measure>
    <time_frame>In the first year of life.</time_frame>
    <description>Viruses present in the nasofarynx during complaints of lower respiratory tract infection or wheezing. Nasofaryngeal swabs will be taken in case of complaints during the first year of life. In the second year of life this will not be done.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication use (bronchodilators, corticosteroids, antibiotics)</measure>
    <time_frame>In the first and second year of life.</time_frame>
    <description>Recorded by short weekly questionnaires (which will be filled in during the first year of life) and more extensive questionnaires every six months in the first and second year of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function as measured by expiratory variability index (Ventica)</measure>
    <time_frame>In the first year of life.</time_frame>
    <description>Measured at age 6-10 weeks (baseline), 6 months and 12 months in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires</measure>
    <time_frame>In the first and second year of life.</time_frame>
    <description>Recorded by extensive questionnaires every six months in the first and second year of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(serious) adverse events</measure>
    <time_frame>In the first year of life.</time_frame>
    <description>Will be reported by parents immediately. Respiratory episodes are not regarded as an (S)AE since these episodes comprise primary and secondary outcomes. (S)AE's are only expected in the first year of life because the treatment stops at the age of 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum specific IgE (allergen sensitization) at 12 months</measure>
    <time_frame>At age 12 months</time_frame>
    <description>Total IgE and house dust mite specific IgE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant vaccination titers at 12 months</measure>
    <time_frame>At age 12 months</time_frame>
    <description>Vaccination titers of haemohilus influenza type B, pneumococci, tetanus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs- and cost-effectiveness</measure>
    <time_frame>In the first and second year of life.</time_frame>
    <description>Estimated from information from standardized questionnaires</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gut and respiratory microbiome composition</measure>
    <time_frame>In the first year of life.</time_frame>
    <description>Measured from faeces and nasofaryngeal swabs taken at age 6-10 weeks, 6 months and 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secretory IgA in saliva</measure>
    <time_frame>In the first year of life</time_frame>
    <description>Saliva will be collected at age 6-10 weeks, 6 months and 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune maturation: immune cells in nasal epithelium</measure>
    <time_frame>In the first year of life</time_frame>
    <description>Collected by nasal scraping at age 6-10 weeks, 6 months and 12 months. Analysed using masscytometry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune maturation: chemokines and cytokines in nasal lining fluid</measure>
    <time_frame>In the first year of life</time_frame>
    <description>Collected by nasosorption at age 6-10 weeks, 6 months and 12 months. Analysed using Luminex cyto/chemokine assay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune maturation: immune cells in bloodsamples</measure>
    <time_frame>In the first year of life</time_frame>
    <description>Collected by blooddraws at age 6-10 weeks, 6 months and 12 months. Analysed using masscytometry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum IgE (total and specific to house dust mite)</measure>
    <time_frame>At age 12 months</time_frame>
    <description>Measured in blood samples which will be drawn at age 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune maturation: Single cell transcriptomics</measure>
    <time_frame>At age 12 months</time_frame>
    <description>Performed on blood drawn at age 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Whole blood stimulation essays</measure>
    <time_frame>At age 12 months</time_frame>
    <description>Performed on blood drawn at age 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers predictive of high morbidity and/or treatment success</measure>
    <time_frame>In the first year of life.</time_frame>
    <description>From combined microbial and immunological data</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Wheezing</condition>
  <condition>LRTI</condition>
  <condition>Premature</condition>
  <arm_group>
    <arm_group_label>Broncho-Vaxom treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants in this arm will be given 3,5mg bacterial lysate (OM-85) 10 days per month from 6 weeks after birth until 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants in this arm will be given a placebo powder from a capsule that will be indistinguishable from the active study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Broncho-Vaxom</intervention_name>
    <description>Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.</description>
    <arm_group_label>Broncho-Vaxom treatment</arm_group_label>
    <other_name>OM-85</other_name>
    <other_name>Broncho-Vaxom concentrate (Bacterial lysate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age at delivery between 30+0 and 35+6 weeks&#xD;
&#xD;
          -  Postnatal age at least 6 weeks at randomization &amp; postmenstrual age at least 37 weeks&#xD;
&#xD;
          -  Written informed consent by both parents or formal caregivers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underlying other severe respiratory disease such as broncho-pulmonary dysplasia&#xD;
             (unexpected in this group); hemodynamic significant cardiac disease;&#xD;
             immunodefi-ciency; severe failure to thrive; birth asphyxia with predicted poor&#xD;
             neurological out-come; syndrome or serious congenital disorder.&#xD;
&#xD;
          -  Lower RTI before randomization&#xD;
&#xD;
          -  Dysmaturity and/or weight &lt; 2.5 kg at age of randomization.&#xD;
&#xD;
          -  Maternal TNF-alpha inhibitors or other immunosuppression during pregnancy and/or&#xD;
             breastfeeding&#xD;
&#xD;
          -  Parents unable to speak and read Dutch/English language&#xD;
&#xD;
          -  Known allergic hypersensitivity to the active ingredients/substance or to any of the&#xD;
             excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Haataja P, Korhonen P, Ojala R, Hirvonen M, Korppi M, Gissler M, Luukkaala T, Tammela O. Hospital admissions for lower respiratory tract infections in children born moderately/late preterm. Pediatr Pulmonol. 2018 Feb;53(2):209-217. doi: 10.1002/ppul.23908. Epub 2017 Nov 29.</citation>
    <PMID>29193814</PMID>
  </reference>
  <reference>
    <citation>Pramana IA, Latzin P, Schlapbach LJ, Hafen G, Kuehni CE, Nelle M, Riedel T, Frey U. Respiratory symptoms in preterm infants: burden of disease in the first year of life. Eur J Med Res. 2011 May 12;16(5):223-30.</citation>
    <PMID>21719396</PMID>
  </reference>
  <reference>
    <citation>Vrijlandt EJ, Kerstjens JM, Duiverman EJ, Bos AF, Reijneveld SA. Moderately preterm children have more respiratory problems during their first 5 years of life than children born full term. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1234-40. doi: 10.1164/rccm.201211-2070OC.</citation>
    <PMID>23525931</PMID>
  </reference>
  <reference>
    <citation>Pérez-Yarza EG, Moreno-Galdó A, Ramilo O, Rubí T, Escribano A, Torres A, Sardón O, Oliva C, Pérez G, Cortell I, Rovira-Amigo S, Pastor-Vivero MD, Pérez-Frías J, Velasco V, Torres-Borrego J, Figuerola J, Barrio MI, García-Hernández G, Mejías A; SAREPREM 3235 investigators. Risk factors for bronchiolitis, recurrent wheezing, and related hospitalization in preterm infants during the first year of life. Pediatr Allergy Immunol. 2015 Dec;26(8):797-804. doi: 10.1111/pai.12414. Epub 2015 Jul 1.</citation>
    <PMID>26031206</PMID>
  </reference>
  <reference>
    <citation>Edwards MO, Kotecha SJ, Lowe J, Richards L, Watkins WJ, Kotecha S. Management of Prematurity-Associated Wheeze and Its Association with Atopy. PLoS One. 2016 May 20;11(5):e0155695. doi: 10.1371/journal.pone.0155695. eCollection 2016.</citation>
    <PMID>27203564</PMID>
  </reference>
  <reference>
    <citation>Kotecha S, Clemm H, Halvorsen T, Kotecha SJ. Bronchial hyper-responsiveness in preterm-born subjects: A systematic review and meta-analysis. Pediatr Allergy Immunol. 2018 Nov;29(7):715-725. doi: 10.1111/pai.12957. Epub 2018 Sep 5.</citation>
    <PMID>30014518</PMID>
  </reference>
  <reference>
    <citation>Moschino L, Carraro S, Baraldi E. Early-life origin and prevention of chronic obstructive pulmonary diseases. Pediatr Allergy Immunol. 2020 Feb;31 Suppl 24:16-18. doi: 10.1111/pai.13157.</citation>
    <PMID>32017219</PMID>
  </reference>
  <reference>
    <citation>Tirone C, Pezza L, Paladini A, Tana M, Aurilia C, Lio A, D'Ippolito S, Tersigni C, Posteraro B, Sanguinetti M, Di Simone N, Vento G. Gut and Lung Microbiota in Preterm Infants: Immunological Modulation and Implication in Neonatal Outcomes. Front Immunol. 2019 Dec 12;10:2910. doi: 10.3389/fimmu.2019.02910. eCollection 2019. Review.</citation>
    <PMID>31921169</PMID>
  </reference>
  <reference>
    <citation>Stewart CJ, Embleton ND, Marrs EC, Smith DP, Nelson A, Abdulkadir B, Skeath T, Petrosino JF, Perry JD, Berrington JE, Cummings SP. Temporal bacterial and metabolic development of the preterm gut reveals specific signatures in health and disease. Microbiome. 2016 Dec 29;4(1):67. doi: 10.1186/s40168-016-0216-8.</citation>
    <PMID>28034304</PMID>
  </reference>
  <reference>
    <citation>Arboleya S, Binetti A, Salazar N, Fernández N, Solís G, Hernández-Barranco A, Margolles A, de Los Reyes-Gavilán CG, Gueimonde M. Establishment and development of intestinal microbiota in preterm neonates. FEMS Microbiol Ecol. 2012 Mar;79(3):763-72. doi: 10.1111/j.1574-6941.2011.01261.x. Epub 2011 Dec 15.</citation>
    <PMID>22126419</PMID>
  </reference>
  <reference>
    <citation>Hill CJ, Lynch DB, Murphy K, Ulaszewska M, Jeffery IB, O'Shea CA, Watkins C, Dempsey E, Mattivi F, Tuohy K, Ross RP, Ryan CA, O' Toole PW, Stanton C. Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET Cohort. Microbiome. 2017 Jan 17;5(1):4. doi: 10.1186/s40168-016-0213-y. Erratum in: Microbiome. 2017 Feb 14;5(1):21.</citation>
    <PMID>28095889</PMID>
  </reference>
  <reference>
    <citation>Pattaroni C, Watzenboeck ML, Schneidegger S, Kieser S, Wong NC, Bernasconi E, Pernot J, Mercier L, Knapp S, Nicod LP, Marsland CP, Roth-Kleiner M, Marsland BJ. Early-Life Formation of the Microbial and Immunological Environment of the Human Airways. Cell Host Microbe. 2018 Dec 12;24(6):857-865.e4. doi: 10.1016/j.chom.2018.10.019. Epub 2018 Nov 29.</citation>
    <PMID>30503510</PMID>
  </reference>
  <reference>
    <citation>Carraro S, Scheltema N, Bont L, Baraldi E. Early-life origins of chronic respiratory diseases: understanding and promoting healthy ageing. Eur Respir J. 2014 Dec;44(6):1682-96. doi: 10.1183/09031936.00084114. Epub 2014 Oct 16. Review.</citation>
    <PMID>25323240</PMID>
  </reference>
  <reference>
    <citation>Martinez FD. Childhood Asthma Inception and Progression: Role of Microbial Exposures, Susceptibility to Viruses and Early Allergic Sensitization. Immunol Allergy Clin North Am. 2019 May;39(2):141-150. doi: 10.1016/j.iac.2018.12.001. Review.</citation>
    <PMID>30954166</PMID>
  </reference>
  <reference>
    <citation>Abreo A, Wu P, Donovan BM, Ding T, Gebretsadik T, Huang X, Stone CA, Turi KN, Hartert TV. Infant Respiratory Syncytial Virus Bronchiolitis and Subsequent Risk of Pneumonia, Otitis Media, and Antibiotic Utilization. Clin Infect Dis. 2020 Jun 24;71(1):211-214. doi: 10.1093/cid/ciz1033.</citation>
    <PMID>31630167</PMID>
  </reference>
  <reference>
    <citation>Melville JM, Moss TJ. The immune consequences of preterm birth. Front Neurosci. 2013 May 21;7:79. doi: 10.3389/fnins.2013.00079. eCollection 2013.</citation>
    <PMID>23734091</PMID>
  </reference>
  <reference>
    <citation>McGreal EP, Hearne K, Spiller OB. Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth. Immunobiology. 2012 Feb;217(2):176-86. doi: 10.1016/j.imbio.2011.07.027. Epub 2011 Jul 30. Review.</citation>
    <PMID>21868122</PMID>
  </reference>
  <reference>
    <citation>Olin A, Henckel E, Chen Y, Lakshmikanth T, Pou C, Mikes J, Gustafsson A, Bernhardsson AK, Zhang C, Bohlin K, Brodin P. Stereotypic Immune System Development in Newborn Children. Cell. 2018 Aug 23;174(5):1277-1292.e14. doi: 10.1016/j.cell.2018.06.045.</citation>
    <PMID>30142345</PMID>
  </reference>
  <reference>
    <citation>Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12204-9. doi: 10.1073/pnas.0909122107. Epub 2010 Jun 21.</citation>
    <PMID>20566854</PMID>
  </reference>
  <reference>
    <citation>Sjögren YM, Tomicic S, Lundberg A, Böttcher MF, Björkstén B, Sverremark-Ekström E, Jenmalm MC. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin Exp Allergy. 2009 Dec;39(12):1842-51. doi: 10.1111/j.1365-2222.2009.03326.x. Epub 2009 Sep 3.</citation>
    <PMID>19735274</PMID>
  </reference>
  <reference>
    <citation>Dzidic M, Abrahamsson TR, Artacho A, Björkstén B, Collado MC, Mira A, Jenmalm MC. Aberrant IgA responses to the gut microbiota during infancy precede asthma and allergy development. J Allergy Clin Immunol. 2017 Mar;139(3):1017-1025.e14. doi: 10.1016/j.jaci.2016.06.047. Epub 2016 Aug 13.</citation>
    <PMID>27531072</PMID>
  </reference>
  <reference>
    <citation>Matías V, San Feliciano L, Fernández JE, Lapeña S, Garrido E, Ardura J, Soga MJ, Aragón MP, Remesal A, Benito F, Andrés J, Centeno F, Marugán V, Bachiller R, Bermejo-Martin JF. Host and environmental factors influencing respiratory secretion of pro-wheezing biomarkers in preterm children. Pediatr Allergy Immunol. 2012 Aug;23(5):441-7. doi: 10.1111/j.1399-3038.2012.01269.x. Epub 2012 May 3.</citation>
    <PMID>22554061</PMID>
  </reference>
  <reference>
    <citation>Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, Holt BJ, Hales BJ, Walker ML, Hollams E, Bochkov YA, Grindle K, Johnston SL, Gern JE, Sly PD, Holt PG, Holt KE, Inouye M. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe. 2015 May 13;17(5):704-15. doi: 10.1016/j.chom.2015.03.008. Epub 2015 Apr 9.</citation>
    <PMID>25865368</PMID>
  </reference>
  <reference>
    <citation>Thorsen J, Rasmussen MA, Waage J, Mortensen M, Brejnrod A, Bønnelykke K, Chawes BL, Brix S, Sørensen SJ, Stokholm J, Bisgaard H. Infant airway microbiota and topical immune perturbations in the origins of childhood asthma. Nat Commun. 2019 Nov 1;10(1):5001. doi: 10.1038/s41467-019-12989-7.</citation>
    <PMID>31676759</PMID>
  </reference>
  <reference>
    <citation>Vissing NH, Larsen JM, Rasmussen MA, Chawes BL, Thysen AH, Bønnelykke K, Brix S, Bisgaard H. Susceptibility to Lower Respiratory Infections in Childhood is Associated with Perturbation of the Cytokine Response to Pathogenic Airway Bacteria. Pediatr Infect Dis J. 2016 May;35(5):561-6. doi: 10.1097/INF.0000000000001092.</citation>
    <PMID>26910587</PMID>
  </reference>
  <reference>
    <citation>Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013 May 9;368(19):1791-9. doi: 10.1056/NEJMoa1211917. Erratum in: N Engl J Med. 2016 Jun 16;374(24):2406.</citation>
    <PMID>23656644</PMID>
  </reference>
  <reference>
    <citation>Luoto R, Ruuskanen O, Waris M, Kalliomäki M, Salminen S, Isolauri E. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2014 Feb;133(2):405-13. doi: 10.1016/j.jaci.2013.08.020. Epub 2013 Oct 13.</citation>
    <PMID>24131826</PMID>
  </reference>
  <reference>
    <citation>Niele N, van Zwol A, Westerbeek EA, Lafeber HN, van Elburg RM. Effect of non-human neutral and acidic oligosaccharides on allergic and infectious diseases in preterm infants. Eur J Pediatr. 2013 Mar;172(3):317-23. doi: 10.1007/s00431-012-1886-2. Epub 2012 Nov 7.</citation>
    <PMID>23132642</PMID>
  </reference>
  <reference>
    <citation>Pfefferle PI, Prescott SL, Kopp M. Microbial influence on tolerance and opportunities for intervention with prebiotics/probiotics and bacterial lysates. J Allergy Clin Immunol. 2013 Jun;131(6):1453-63; quiz 1464. doi: 10.1016/j.jaci.2013.03.020. Epub 2013 May 2. Review.</citation>
    <PMID>23643095</PMID>
  </reference>
  <reference>
    <citation>Yin J, Xu B, Zeng X, Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol. 2018 Jan;54:198-209. doi: 10.1016/j.intimp.2017.10.032. Epub 2017 Nov 16. Review.</citation>
    <PMID>29154122</PMID>
  </reference>
  <reference>
    <citation>Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2012 Feb;25(1):62-8. doi: 10.1016/j.pupt.2011.11.002. Epub 2011 Nov 27. Review.</citation>
    <PMID>22155205</PMID>
  </reference>
  <reference>
    <citation>Razi CH, Harmancı K, Abacı A, Özdemir O, Hızlı S, Renda R, Keskin F. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol. 2010 Oct;126(4):763-9. doi: 10.1016/j.jaci.2010.07.038.</citation>
    <PMID>20920766</PMID>
  </reference>
  <reference>
    <citation>Esposito S, Bianchini S, Bosis S, Tagliabue C, Coro I, Argentiero A, Principi N. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J Transl Med. 2019 Aug 23;17(1):284. doi: 10.1186/s12967-019-2040-y.</citation>
    <PMID>31443716</PMID>
  </reference>
  <reference>
    <citation>de Boer GM, Żółkiewicz J, Strzelec KP, Ruszczyński M, Hendriks RW, Braunstahl GJ, Feleszko W, Tramper-Stranders GA. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. Eur Respir Rev. 2020 Nov 27;29(158). pii: 190175. doi: 10.1183/16000617.0175-2019. Print 2020 Dec 31. Review.</citation>
    <PMID>33246991</PMID>
  </reference>
  <reference>
    <citation>Sly PD, Galbraith S, Islam Z, Holt B, Troy N, Holt PG. Primary prevention of severe lower respiratory illnesses in at-risk infants using the immunomodulator OM-85. J Allergy Clin Immunol. 2019 Sep;144(3):870-872.e11. doi: 10.1016/j.jaci.2019.05.032. Epub 2019 Jun 8.</citation>
    <PMID>31185221</PMID>
  </reference>
  <reference>
    <citation>Lau S, Gerhold K, Zimmermann K, Ockeloen CW, Rossberg S, Wagner P, Sulser C, Bunikowski R, Witt I, Wauer J, Beschorner J, Menke G, Hamelmann E, Wahn U. Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012 Apr;129(4):1040-7. doi: 10.1016/j.jaci.2012.02.005.</citation>
    <PMID>22464674</PMID>
  </reference>
  <reference>
    <citation>Esposito S, Marchisio P, Prada E, Daleno C, Porretti L, Carsetti R, Bosco A, Ierardi V, Scala A, Principi N. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014 May 7;32(22):2546-52. doi: 10.1016/j.vaccine.2014.03.055. Epub 2014 Mar 26.</citation>
    <PMID>24681270</PMID>
  </reference>
  <reference>
    <citation>Seppä VP, Paassilta M, Kivistö J, Hult A, Viik J, Gracia-Tabuenca J, Karjalainen J. Reduced expiratory variability index (EVI) is associated with controller medication withdrawal and symptoms in wheezy children aged 1-5 years. Pediatr Allergy Immunol. 2020 Jul;31(5):489-495. doi: 10.1111/pai.13234. Epub 2020 Mar 17.</citation>
    <PMID>32068911</PMID>
  </reference>
  <reference>
    <citation>de Ruiter K, Jochems SP, Tahapary DL, Stam KA, König M, van Unen V, Laban S, Höllt T, Mbow M, Lelieveldt BPF, Koning F, Sartono E, Smit JWA, Supali T, Yazdanbakhsh M. Helminth infections drive heterogeneity in human type 2 and regulatory cells. Sci Transl Med. 2020 Jan 1;12(524). pii: eaaw3703. doi: 10.1126/scitranslmed.aaw3703.</citation>
    <PMID>31894102</PMID>
  </reference>
  <reference>
    <citation>Jochems SP, de Ruiter K, Solórzano C, Voskamp A, Mitsi E, Nikolaou E, Carniel BF, Pojar S, German EL, Reiné J, Soares-Schanoski A, Hill H, Robinson R, Hyder-Wright AD, Weight CM, Durrenberger PF, Heyderman RS, Gordon SB, Smits HH, Urban BC, Rylance J, Collins AM, Wilkie MD, Lazarova L, Leong SC, Yazdanbakhsh M, Ferreira DM. Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization. J Clin Invest. 2019 Jul 30;129(10):4523-4538. doi: 10.1172/JCI128865.</citation>
    <PMID>31361601</PMID>
  </reference>
  <reference>
    <citation>Beyrend G, Stam K, Höllt T, Ossendorp F, Arens R. Cytofast: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations. Comput Struct Biotechnol J. 2018 Oct 24;16:435-442. doi: 10.1016/j.csbj.2018.10.004. eCollection 2018.</citation>
    <PMID>30450167</PMID>
  </reference>
  <reference>
    <citation>Galazzo G, van Best N, Bervoets L, Dapaah IO, Savelkoul PH, Hornef MW; GI-MDH consortium, Lau S, Hamelmann E, Penders J. Development of the Microbiota and Associations With Birth Mode, Diet, and Atopic Disorders in a Longitudinal Analysis of Stool Samples, Collected From Infancy Through Early Childhood. Gastroenterology. 2020 May;158(6):1584-1596. doi: 10.1053/j.gastro.2020.01.024. Epub 2020 Jan 18.</citation>
    <PMID>31958431</PMID>
  </reference>
  <reference>
    <citation>Badurdeen S, Marshall A, Daish H, Hatherill M, Berkley JA. Safety and Immunogenicity of Early Bacillus Calmette-Guérin Vaccination in Infants Who Are Preterm and/or Have Low Birth Weights: A Systematic Review and Meta-analysis. JAMA Pediatr. 2019 Jan 1;173(1):75-85. doi: 10.1001/jamapediatrics.2018.4038.</citation>
    <PMID>30476973</PMID>
  </reference>
  <reference>
    <citation>Stein MM, Hrusch CL, Gozdz J, Igartua C, Pivniouk V, Murray SE, Ledford JG, Marques Dos Santos M, Anderson RL, Metwali N, Neilson JW, Maier RM, Gilbert JA, Holbreich M, Thorne PS, Martinez FD, von Mutius E, Vercelli D, Ober C, Sperling AI. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med. 2016 Aug 4;375(5):411-421. doi: 10.1056/NEJMoa1508749.</citation>
    <PMID>27518660</PMID>
  </reference>
  <reference>
    <citation>Karaca NE, Gulez N, Aksu G, Azarsiz E, Kutukculer N. Does OM-85 BV prophylaxis trigger autoimmunity in IgA deficient children? Int Immunopharmacol. 2011 Nov;11(11):1747-51. doi: 10.1016/j.intimp.2011.06.009. Epub 2011 Jul 21.</citation>
    <PMID>21771668</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Franciscus Gasthuis</investigator_affiliation>
    <investigator_full_name>Gerdien Tramper</investigator_full_name>
    <investigator_title>Pediatrician/clinical researcher, principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiratory Sounds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Broncho-Vaxom</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchdata will be shared in data repositories according to the FAIR principle. Clinical data about respiratory health will be shared in the DANS repository. Inlcuding metadata which will ensure reusability. Sequencing data will be shared online in the ENA repository which will provide an unique global identifier. All used bioinformatics pipelines for data analysis will be made accessible on a GitHub account. Immunological data will be shared in NCBI Gene Expression omnibus and ImmPort. Used analysis pipelines for the transcriptomics data will also be tracked and can be shared using a Github account.&#xD;
All data shared will be pneudonymized.</ipd_description>
    <ipd_time_frame>Data will come available after publication of the data in articles by initating researchers.</ipd_time_frame>
    <ipd_access_criteria>Data will be available under restricted access. A request for data sharing will include at least the reason for request (for what will the receiver use the data?) and agreements about authorship.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

